Miltefosine

Kathryn Dzintars, Pharm.D., BCPS
Pediatric Dosing Author: Lisa Hutchins, Pharm.D.
Miltefosine is a topic covered in the Johns Hopkins ABX Guide.

To view the entire topic, please or .

Pediatrics Central™ is an all-in-one application that puts valuable medical information, via your mobile device or the web, in the hands of clinicians treating infants, children, and adolescents. Explore these free sample topics:

-- The first section of this topic is shown below --

INDICATIONS

FDA

  • Treatment of cutaneous, mucosal, and visceral leishmaniasis in patients >12 years of age.
  • Miltefosine no longer needs to be obtained through the CDC.

NON-FDA APPROVED USES

  • Treatment of free-living amoeba, including primary meningoencephalitis (PAM) caused by Naegleria fowleri and granulomatous amebic encephalitis (GAM) caused by Balamuthia mandrillaris and Acanthamoeba species.
  • Use in combination with voriconazole and terbinafine for the management of Scedosporium prolificans

-- To view the remaining sections of this topic, please or --

INDICATIONS

FDA

  • Treatment of cutaneous, mucosal, and visceral leishmaniasis in patients >12 years of age.
  • Miltefosine no longer needs to be obtained through the CDC.

NON-FDA APPROVED USES

  • Treatment of free-living amoeba, including primary meningoencephalitis (PAM) caused by Naegleria fowleri and granulomatous amebic encephalitis (GAM) caused by Balamuthia mandrillaris and Acanthamoeba species.
  • Use in combination with voriconazole and terbinafine for the management of Scedosporium prolificans

There's more to see -- the rest of this entry is available only to subscribers.

Last updated: September 3, 2019